HilleVax abandons its norovirus vaccine (2024)
HilleVax's infant norovirus vaccine, HIL-214, showed just 5% efficacy in a trial of more than 2,800 babies. The company cut about 40% of staff and dropped the program. Its shares fell sharply.
HilleVax pivoted away from its lead product and the infant norovirus effort ended.
The failure narrowed the field and raised doubts about how easily norovirus immunity can be induced.
It shows norovirus is a graveyard for vaccine candidates. Moderna's miss fits a pattern, not a one-off.
